• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

西罗莫司（雷帕霉素）诱导抗肿瘤坏死因子难治性小儿溃疡性结肠炎的黏膜愈合。

Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis.

作者信息

Kellermayer Richard, Chang Andrew, Patel Kalyani

机构信息

Section of Pediatric Gastroenterology, Texas Children's Hospital Baylor College of Medicine.

USDA/ARS Children's Nutrition Research Center.

出版信息

JPGN Rep. 2022 Mar 17;3(2):e183. doi: 10.1097/PG9.0000000000000183. eCollection 2022 May.

DOI:10.1097/PG9.0000000000000183
PMID:37168909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10158451/
Abstract

Sirolimus (rapamycin) has been sparsely reported in the treatment of pediatric ulcerative colitis (PUC). Mucosal healing has not been examined in responders to the drug. We describe a case of infliximab refractory PUC where rapamycin induced sustained clinical remission along with mucosal healing. We conclude that rapamycin should be positioned into the expanding treatment repertoire of PUC.

摘要

西罗莫司（雷帕霉素）用于治疗儿童溃疡性结肠炎（PUC）的报道较少。尚未对该药物治疗有效的患者进行黏膜愈合情况的检查。我们描述了1例英夫利昔单抗难治性PUC病例，雷帕霉素诱导了持续的临床缓解并伴有黏膜愈合。我们得出结论，雷帕霉素应纳入不断扩大的PUC治疗方法中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf4/10158451/7bb49c1c78a4/pg9-3-e183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf4/10158451/7bb49c1c78a4/pg9-3-e183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf4/10158451/7bb49c1c78a4/pg9-3-e183-g001.jpg

相似文献

1
Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis.西罗莫司（雷帕霉素）诱导抗肿瘤坏死因子难治性小儿溃疡性结肠炎的黏膜愈合。
JPGN Rep. 2022 Mar 17;3(2):e183. doi: 10.1097/PG9.0000000000000183. eCollection 2022 May.
2
The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children.西罗莫司（雷帕霉素）在儿童难治性炎症性肠病治疗中的应用。
J Crohns Colitis. 2014 Dec;8(12):1730-4. doi: 10.1016/j.crohns.2014.08.014. Epub 2014 Sep 18.
3
Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.肿瘤坏死因子α阻断剂治疗对传统药物治疗不耐受或难治的溃疡性结肠炎：一项荟萃分析。
PLoS One. 2014 Jan 27;9(1):e86692. doi: 10.1371/journal.pone.0086692. eCollection 2014.
4
Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.非侵入性生物标志物作为难治性溃疡性结肠炎患者英夫利昔单抗诱导治疗后临床和内镜缓解的替代预测指标。
Saudi J Gastroenterol. 2017 Jul-Aug;23(4):238-245. doi: 10.4103/sjg.SJG_599_16.
5
Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.内镜和临床变量可预测接受英夫利昔单抗治疗的溃疡性结肠炎患儿的缓解持续时间。
Clin Gastroenterol Hepatol. 2013 Nov;11(11):1460-5. doi: 10.1016/j.cgh.2013.04.049. Epub 2013 May 11.
6
Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials.基于性别差异的肿瘤坏死因子抑制剂治疗溃疡性结肠炎反应的个体参与者数据荟萃分析：临床试验。
Inflamm Bowel Dis. 2023 Jan 5;29(1):1-8. doi: 10.1093/ibd/izac067.
7
Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.黏膜肿瘤坏死因子-α 正常化：溃疡性结肠炎中停用英夫利昔单抗治疗的新标准。
Cytokine. 2016 Mar;79:90-5. doi: 10.1016/j.cyto.2015.12.021. Epub 2016 Jan 8.
8
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.用于诱导溃疡性结肠炎缓解的肿瘤坏死因子α阻断剂。
Cochrane Database Syst Rev. 2006 Jul 19(3):CD005112. doi: 10.1002/14651858.CD005112.pub2.
9
Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.肿瘤坏死因子拮抗剂在溃疡性结肠炎缓解、结肠切除术和住院治疗中的疗效：安慰剂对照试验的荟萃分析。
Dig Liver Dis. 2015 May;47(5):356-64. doi: 10.1016/j.dld.2015.01.148. Epub 2015 Jan 22.
10
Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.接受抗TNF治疗的溃疡性结肠炎患者组织愈合的预测因素。
Dig Liver Dis. 2017 Jan;49(1):29-33. doi: 10.1016/j.dld.2016.10.008. Epub 2016 Oct 20.

引用本文的文献

1
mTORC1 activation in presumed classical monocytes: observed correlation with human size variation and neuropsychiatric disease.推测经典单核细胞中 mTORC1 的激活：与人类体型变化和神经精神疾病的观察相关性。
Aging (Albany NY). 2024 Jul 26;16(14):11134-11150. doi: 10.18632/aging.206033.
2
Sirolimus Use in Refractory Crohn's Disease.西罗莫司在难治性克罗恩病中的应用。
ACG Case Rep J. 2024 Jun 14;11(6):e01368. doi: 10.14309/crj.0000000000001368. eCollection 2024 Jun.
3
Interactions of Autophagy and the Immune System in Health and Diseases.

本文引用的文献

1
Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis.生物制剂时代的结肠切除术进展：小儿溃疡性结肠炎的单中心经验。
J Pediatr Surg. 2020 Sep;55(9):1815-1823. doi: 10.1016/j.jpedsurg.2020.01.054. Epub 2020 Feb 3.
2
Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.标准化小儿结肠炎治疗反应的临床和生物学预测因子（PROTECT）：一项多中心发病队列研究。
Lancet. 2019 Apr 27;393(10182):1708-1720. doi: 10.1016/S0140-6736(18)32592-3. Epub 2019 Mar 29.
3
Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
自噬与免疫系统在健康和疾病中的相互作用。
Autophagy Rep. 2022;1(1):438-515. doi: 10.1080/27694127.2022.2119743. Epub 2022 Oct 5.
4
Evaluation of the mTORC activity in the presence of Toxoplasma gondii and azathioprine in human monocyte cell line.评价人单核细胞系中弓形虫和巯嘌呤存在时的 mTORC 活性。
BMC Microbiol. 2023 Mar 21;23(1):77. doi: 10.1186/s12866-023-02819-8.
儿科溃疡性结肠炎的管理，第 2 部分：急性重度结肠炎——来自欧洲克罗恩病和结肠炎组织以及欧洲儿童胃肠病学、肝病学和营养学学会的循证共识指南。
J Pediatr Gastroenterol Nutr. 2018 Aug;67(2):292-310. doi: 10.1097/MPG.0000000000002036.
4
Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.西罗莫司治疗复杂血管异常的疗效与安全性。
Pediatrics. 2016 Feb;137(2):e20153257. doi: 10.1542/peds.2015-3257. Epub 2016 Jan 18.
5
The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children.西罗莫司（雷帕霉素）在儿童难治性炎症性肠病治疗中的应用。
J Crohns Colitis. 2014 Dec;8(12):1730-4. doi: 10.1016/j.crohns.2014.08.014. Epub 2014 Sep 18.